Thursday, 15 September 2022

LEMMING INVESTOR RESEARCH NEWSLETTER & SMALL COMPANY CHAMPION - SUBSCRIPTION

Small Company Champion and Lemming Investor Research Newsletter are operated and run by investors for investors. We have decades of experience in the stock markets; therefore, we have a wealth of knowledge that has forced us to adapt to each market crash; our first was way back in October 1987. 

The first contemporary global financial crisis unfolded on October 19, 1987, a day known as “Black Monday,” when the Dow Jones Industrial Average dropped 22.6 per cent. The editor, Elric Langton, had been investing for just 9-months - a baptism not forgotten. 

If you are relatively new to investing, you will be forgiven for thinking market crash events are rare; they are not. However, market crashes, or meltdowns, are far more regular than you may think.

There have been regular market turmoil, market crashes, or global crisis; call them what you like, and the result is the same. Portfolio turmoil!

We have gained the trust and respect of several companies we have featured over the years. They trust us to be balanced and informative; therefore, we often become the conduit between investors and companies. 

We appreciate time can be a premium for busy people, and time spent researching companies is time lost with the family and loved ones and hobbies and pursuits far more exciting than ploughing through the internet researching the next multibagger.

We operate two different subscription-based services

We know many investors with very different ideas and strategies; therefore, we have adapted to keep two distinct disciplines separate. But first, some statistics on Companies we have featured across both publications.

Our recent history (2019-2022

We do not claim to get it right 100% of the time. Still, when we do, our research has resulted in unearthing plenty of multi-baggers, such as Ava Risk Group ($0.12c high of $0.79c) PowerHouse Energy (0.25p high of 10p) Itaconix (5.50p high of 17p) SkinBioTherapeutics (9p high of 77p), Seeing Machines (4.4p high of 13p) OptiBiotix Health (55p high of 133p) Open Orphan (21p high of 48p). 

Not all multi-bag, of course; some of my more sedate featured companies like Warehouse Reit (115p High of 178p), Ramsdons Holding (140p high of 222p), and Equals (40p High of 99p), Calnex Solutions (130p high 179p), ME Group International formerly Photo-Me (71p high 119p), the list goes on

We do our best to broaden our research across the LSE, AIM, ASX, NASDAQ and the NYSE, where one of our more recent features, Livent Corporation, at $21.31c and looking excellent value on a 2-3 year view and beyond on the back of significant demand for electric vehicles surges around the world. In addition, we have highlighted a raft of up-and-coming Companies we expect to ride the EV craze, the need for lithium, and supporting industries.

Lemming Investor Research Newsletter

We aim to discover early-stage disruptive companies, which can be difficult to hold as an investment; therefore, it is vital to garner as much information as possible. This allows for informed decisions and less speculation. But, their very nature is far more volatile than the companies featured in Small Company Champion. 

We avoid the social media frenzy nature of Telegram, WhatsApp and Twitter groups because our experience tells us some of the moderators are already invested and often pump their book for new lemmings while they sell on the rise. This tactic is widespread around speculative stocks, so please avoid these groups. Twitter and financial forums should not be classed as research.

We declare all financial interests in any Company we feature. We also inform our subscribers of our intention to sell at least 24 hours before we do. 


Small Company Champion

This site has a defined set of filters designed to seek companies’ best growth opportunities. These companies will be established with a history of delivering on corporate strategy. Some of these would pay regular dividends and are therefore worthy as income investments if you were inclined. 

We describe these Companies as “Zulu-Esq” (forecasting high earnings growth but currently valued at a low price relative to their forecast earnings.) because they are not expected to attract the same level of excitement as a company with multi-bagger potential or expectations, often unrealistic. But, these are companies you would not expect to spike to all-time highs, then retrace 50 plus per cent, often experienced on the AIM market. Simply put, these are not as volatile as the companies we feature in Lemming Investor Research Newsletter.

We declare all financial interests in any Company we feature. We also inform our subscribers of our intention to sell at least 24 hours before we do. 

 








Sunday, 25 November 2018

OptiBiotix - Partners and Products 2017-2019










AUGUST 2019

OptiBiotix Health (OPTI) management have often spoken about commercial traction building in H2 2018, and break-even YE 2018. We are told break-even turned out to be almost three months early, most of the commercial traction is coming from the ProBiotix technology platform. There is the expectation for an acceleration in commercial traction in 2019, thereafter, exponential growth in 2020 as more of the much larger agreements with multinational partner begin to come on stream, all of which falls to the bottom-line.


We have seen new product launches with Galenicum, Olliscience, and Muscle Form, and Aragan, being the latest find and yet OPTI did not see fit to notify the market, or at least this is the allegation from some quarters. With the exception of Galenicum, where OPTI did notify the market, we will see a growing number of new product launches before the year is out and into 2019 as OPTI distributors sell SlimBiome and LP-LDL products to their clients. These partners will absorb 100% of the sales and marketing spend, not OPTI. The beauty of this is the fact revenues will be building in the background without the wider market realising until it is too late...the patient and the savvy investor will be aware of course.





Partner and Home Brand Product Listings


On Tuesday 19th March Stephen O'Hara confirmed the "majority of partners are generating revenues." The company is already profitable, and more and more of the larger deals signed-off 9 months ago will soon be adding to a rapidly upward revenue trend, which will certainly accelerate into 2020, and yet there even larger deals pregnant


The question is, how many more are out there or about to launch? What we witnessing is the green shoots of the business model developing under the radar.

I'm hoping for a clear sign the hockey stick effect is well ahead of the curve and we get a positive forward-looking statement and promptly reported FY or worse is to come.


In the meantime, I would like to remind investors of the value adding and growing product pipeline that is building momentum, with science-backed and award-winning products.



https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcROpygJuHLu031-hIAVvHMjJZzjGkiU8cEy5fiJ_COcl-K1lIsQ


Products launched and on sale;










http://optibiotix.com/product/cholbiome/



https://www.hlh-biopharma.de/shop/en/intestinal-health/1018.html
http://pharmabiota.com/cholestero-biota.html



https://seed.com/male-daily-synbiotic/

https://www.olliscience.com/sante-anti-age/sante-cardiovasculaire/ollibiotic/






















https://www.muscleform.co.uk/goal/diet-and-weight-control/ultra-mr-ultimate-meal-replacement




The current list of partnerships across the value chain; (updated periodically).


The evergrowing global geographical spread significantly reduces macroeconomic risks associated with each region; Brexit being a prime example.

It is worth noting that each partner is not restricted by said country of origin if they have established international exports they can in some cases distribute outside their home country. Example, Galenicum commercial footprint reached the Middle East, Europe and America's. Some of the agreement is exclusive.


Below is a list of existing agreements (34 - not including the 2 SweetBiotix agreements until signed off) across the commercial supply chains, from manufactures, formulations, and distributors, with the focus being business to business. These agreements have been identified as small ( up to £250k pa), medium (c£500k - £750k pa) and large (£750 - £1m + pa), and multinationals (huge) where estimates could be in excess retail deals once fully operational. These figures are purely intended as a guide to the potential revenues as each one comes on stream. The huge deals with multinationals, like TATA, unnamed US pharma, and retail deals yet to been announced which are expected to yield c£5-6m pa, classed as huge



Updated - 47 Commercial Agreements as of AUGUST 2019


PARTNER & HOME BRAND PRODUCT LISTING HERE.

39ytu Capsa Food - Spain (small) LP-LDL
39ytu - IENP - Capsa Food (large) LP-LDL (available in El Corte Inglés stores in Spain)
Agropur - Canada, Mexico, USA, (SlimBiime) (large)
Akums Drugs and Pharmaceuticals - Pakistan (medium) LP-LDL
Alfasigma - Italy (
medium) LP-LDL
ARAGAN - France (
smallLP-LDL

Aviform Ltd - UK (small) SlimBiome
Bened Biomedical - Taiwan (
small) LP-LDL

BioEnergiser (SlimBiome Medical - UK distributor)Biolat - Estonia, Latvia & Lithuania (small)(LP-LDL)
Biovagen Healthcare - Vietnam (small) LP-LDL
Cambridge Commodities - UK (small) SlimBiome
Cereal Ingredients Inc - USA (medium) SlimBiome
CTC Group - Greece & Cyprus (small) LP-LDL

DKSH - Italy & Spain (large) SlimBiome 
Eiwan Trading Co. Ltd - Japan LP-LDL
Extensor - Poland (GoFigure) (small)
Fine Foods & Pharmaceuticals - Italy (medium) LP-LDL
Formulation Creations - South Africa (small)
Galenicum Special Ingredients - Spain (medium) LP-LDL
GoFigure (The Healthy Weight-loss Company - Majority owned by OPTI) UK (medium) SlimBiome
Gold Coast Ingredients* USA (medium)
HLH BioPharma - Germany (small
LP-LDL

John Morleys - UK (small) SlimBiome 
KAPPA Bioscience (small(LP-LDL Vitamin K2 distributor, 27 countries Europe plus Russia and Singapore)
Knighton Foods (Premier Foods PLC) - UK (small) SlimBiome
Maxum Foods (medium) (SlimBiome - Australia and New Zealand)
Nutrilinea X3 - Italy (largeLP-LDL
OlliScience - Switzerland (small) LP-LDL
Paradise Fruits - Germany (small) SlimBiome
Pharmabiota - New Zealand (small) LP-LDL

Primo Trading - Thailand (small) SlimBiome
Seed Health - USA (large) LP-LDL
Sacco Systems - Italy (large) LP-LDL
SilvexpoRussia and Kazakhstan (medium) CholBiome
Tata Chemicals X 2 (Slimbiome and LPGOS) India (huge)2 x
Trigen Pharma - Pakistan (medium) LP-LDL
US Pharma Lab Inc - USA (
huge) LP-LDL

Velinoff Pharma - Bulgarian (small) CholBiome
Zeon Lifescience - India (large) SlimBiome
Unnamed global corporate ($100bl+ turnover) for SweetBiotix manufacturing & distribution (huge)
USA pharmalab (cholesterol strain) (large) investing c$50m for phase III LP-LDL

Unnamed Bulgarian CE Mark Medical SlimBiome (small)
Mystery US SlimBiome customer thought to be *Gold Coast Ingredients (medium)

DCIT -  LP-LDL China (large)

Thanks to AJS for his detective work uncovering many of the unannounced products/partners


Thanks to Parob for making my life easier compiling the list.

Labels: ,